医薬品受託製造機関 (CMO) 産業の定量的分析：企業構成、市場規模、市場シェア、将来展望
PharmSource - Contract Dose Manufacturing Industry by the Numbers: Composition, Size, Market Share and Outlook - 2019 Edition
|出版日||ページ情報||英文 42 Pages
|医薬品受託製造機関 (CMO) 産業の定量的分析：企業構成、市場規模、市場シェア、将来展望 PharmSource - Contract Dose Manufacturing Industry by the Numbers: Composition, Size, Market Share and Outlook - 2019 Edition|
|出版日: 2019年10月30日||ページ情報: 英文 42 Pages||
当レポートでは、世界の医薬品 (最終製剤) 向け医薬品受託製造機関 (以下CMO) の業界動向について分析し、CMOの企業数・市場規模・市場シェアの推移や、地域別・分野別 (剤型別) の分布傾向、昨今の資本取引動向、今後の業界動向の見通しなどについて調査しております。
The motivation for pharma companies outsourcing their manufacturing is often to do with lacking expertise, equipment, or cost reduction (especially for small to mid-sized CMOs) in development of their product's API or dose. For clinical dose manufacturing, there is a high risk associated with the pipeline drug product and as such using a CMO for this mitigates risk for pharma companies that may otherwise have to invest in equipment and facilities.
This report, the 2019 version in this annual series, characterizes the contract dose manufacturing industry along a number of quantitative dimensions, including number and type of participants, market size, market shares of the top CMOs and profitability. We also assess the outlook for the industry. This report is an improvement over previous reports because it utilizes the integration of Dose manufacturing integration into the GlobalData's Pharma Intelligence Center to provide deeper analysis of the industry.
This expert trend report is a comprehensive look at the finished dose contract manufacturing landscape in 2019, including analysis of dose CMO M&A activity, market size and share. It is a critical source for strategic planning efforts and will improve understanding of crucial components of the supply chain that will provide insights for supplier selection and management.